Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (NASDAQ: LTRN) announced a virtual key opinion leader (KOL) webinar on May 26, 2022, at 12:00 p.m. ET. The webinar will focus on glioblastoma multiforme (GBM) and the potential of their drug candidate LP-184 for treating GBM and other brain cancers. Experts Dr. John Laterra and Dr. Matthias Holdhoff from Johns Hopkins will lead discussions alongside Lantern's Chief Scientific Officer, Dr. Kishor Bhatia. The event coincides with Brain Tumor Awareness Month, highlighting the urgent need for effective treatments for brain cancers.
Lantern Pharma Inc. (NASDAQ: LTRN) announced its participation in five upcoming investor and scientific conferences in
Lantern Pharma (NASDAQ: LTRN) reported Q1 2022 financial results, revealing $65.2 million in cash and equivalents. The company utilizes its RADR® A.I. platform, which surpassed 20 billion data points, enhancing drug discovery capabilities. The HARMONIC™ Phase 2 trial for LP-300 is expected to enroll patients in Summer 2022. Lantern plans to submit an IND for LP-184 by Q3 2022, targeting solid tumors. R&D expenses increased to $2.7 million from $1.3 million year-over-year. A net loss of $4.1 million was recorded, up from $2.5 million in Q1 2021.
Lantern Pharma (NASDAQ: LTRN) announced Dr. Maria L. Maccecchini as a nominee for its Board of Directors during the Annual Meeting on June 8, 2022. Dr. Maccecchini, a seasoned biopharmaceutical executive, brings decades of experience, particularly in neurodegenerative diseases. Concurrently, Leslie W. Kreis, Jr. will not seek reelection. Lantern's President, Panna Sharma, emphasized Dr. Maccecchini's potential contributions to ongoing clinical trials. Lantern is focused on utilizing its RADR® platform to enhance oncology drug development.
Lantern Pharma (NASDAQ: LTRN) plans to release its Q1 2022 financial results on May 3, 2022, after market closure. Management will host a conference call at 4:30 PM ET to discuss these results and outline future milestones. Lantern Pharma utilizes its RADR® A.I. platform in oncology drug development, focusing on genomically-targeted therapeutics. Currently, the company is developing four drug candidates and an ADC program spanning nine tumor targets, with a commitment to optimize patient outcomes.
Lantern Pharma (NASDAQ:LTRN) will be featured on The RedChip Money Report on Bloomberg TV on April 16 at 7 p.m. ET. This program, which reaches approximately 73 million U.S. households, focuses on small-cap investing and includes interviews with company executives and Wall Street analysts. Lantern Pharma utilizes its RADR® AI platform for oncology drug discovery, with a pipeline of four drug candidates and an ADC program targeting eight tumor types, including two in phase 2 trials.
Lantern Pharma (NASDAQ: LTRN) announced an extension of its share repurchase program through July 31, 2022, allowing for the acquisition of up to $7 million in common stock. Since November 2021, the program has seen the repurchase of 475,157 shares at a cost of approximately $3.4 million. An additional $3.6 million is available for future purchases. As of December 31, 2021, the company reported $70.7 million in cash and equivalents, indicating strong liquidity to support the buyback initiative.
Lantern Pharma (NASDAQ: LTRN) announced promising preclinical data for its drug candidate LP-184 at the upcoming AACR annual meeting, scheduled for April 8-13, 2022. LP-184 showed significant anti-tumor activity in brain metastases models from lung, skin, and breast cancers, achieving 6 times greater potency than standard therapies. This small molecule drug targets DNA in cancer cells, particularly beneficial for patients with CNS cancers due to its favorable blood-brain barrier permeability. The FDA has granted LP-184 Orphan Drug and Rare Pediatric Disease designations, expediting its path toward clinical trials.
Lantern Pharma (NASDAQ: LTRN) reported its financial results for Q4 and the fiscal year 2021, marking a pivotal year with significant growth and clinical advancements. The RADR® A.I. platform achieved a remarkable 1,000% growth, surpassing 18 billion data points, and is projected to exceed 25 billion by the end of 2022. The company plans to initiate multiple clinical trials in 2022, including the Phase 2 trial for LP-300 in non-small cell lung cancer. Lantern raised $69 million in 2021, extending its cash runway into 2025, while reporting a net loss of $12.4 million for the year.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, will hold a conference call on March 10, 2022, at 4:30 p.m. ET to discuss its fourth quarter and fiscal year 2021 financial results. Management, led by CEO Panna Sharma, will provide insights into the company's operating performance and guidance on upcoming milestones. Lantern Pharma specializes in oncology drug development leveraging its RADR® A.I. platform to enhance patient targeting for drug trials. The call will also be available via a replay on their investor relations website.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
